News | Radiation Oncology | December 12, 2019

Senate confirms Stephen Hahn, M.D., to serve as FDA Commissioner by Bipartisan Vote of 72-18

“Dr. Hahn can now get to work approving new life-saving drugs and devices, regulating tobacco and e-cigarettes, addressing the opioid crisis, ensuring pain patients can receive the medications they need and protecting our nation’s food supply.” – Senator Lamar Alexander

The American Society for Radiation Oncology (ASTRO) applauded the U.S. Senate for voting today to confirm radiation oncologist Stephen Hahn, M.D., FASTRO, as the next Commissioner of the Food and Drug Administration (FDA).

December 12, 2019 —The American Society for Radiation Oncology (ASTRO) applauded the U.S. Senate for voting today to confirm radiation oncologist Stephen Hahn, M.D., FASTRO, as the next Commissioner of the Food and Drug Administration (FDA).

“We applaud the U.S. Senate for confirming Dr. Stephen Hahn as the nation’s next Commissioner of the Food and Drug Administration. Dr. Hahn’s impressive background as a triple board-certified physician in medicine, medical oncology and radiation oncology coupled with his broad administrative experiences will allow him to ably lead the thousands of career professionals charged with ensuring U.S. consumer protection and public health,” said Theodore L. DeWeese, M.D., FASTRO, Chair of the ASTRO Board of Directors.  “Our support and respect for Dr. Hahn is based on his proven commitment to patients, science-based decision-making, and consumer health and safety. We look forward to his leadership as he steps into this critically important role as FDA Commissioner.”

Senate health committee Chairman Lamar Alexander (R-Tenn.) said that “Dr. Stephen Hahn’s experience as a practicing oncologist, a successful leader of the MD Anderson Cancer Center and work at the National Institutes of Health (NIH) make him the right leader for the FDA at this critical time.”

Hahn was confirmed by the Senate today by a bipartisan vote of 72-18 to serve as commissioner of the U.S. Food and Drug Administration (FDA).

“Dr. Hahn has extensive medical and research experience and is a proven leader in large health systems—all around, he is exactly the type of nominee we want to lead an agency as important as the FDA,” Alexander said. “The Senate health committee I chair received sixteen letters of support for Dr. Hahn representing more than 80 organizations on behalf of doctors, patients, researchers, and from his colleagues. Dr. Hahn has also received support from five previous FDA commissioners, who served under Presidents Trump, Obama and Bush.”

“Dr. Hahn can now get to work approving new life-saving drugs and devices, regulating tobacco and e-cigarettes, addressing the opioid crisis, ensuring pain patients can receive the medications they need and protecting our nation’s food supply.”

Alexander is chairman of the Senate health committee which has jurisdiction over confirmation of the FDA commissioner. Alexander chaired Hahn’s confirmation hearing on November 20, and the committee approved his nomination on December 3 by a bipartisan vote of 18-5. Alexander today voted in favor of Hahn’s nomination.

Hahn has previously served as the chief medical executive at the University of Texas MD Anderson Cancer Center in Houston. He is board certified in both medical oncology and radiation oncology, specializing over the course of his career on prostate, bladder, kidney, testicular, and lung cancers and sarcoma. 

Related content:

ASTRO Congratulates Stephen Hahn, M.D., for Securing Senate Committee Approval to lead FDA

ASTRO supports nomination of Stephen Hahn, M.D., FASTRO, to lead U.S. FDA

Related Content

Results of Journal of the American College of Surgeons study should reassure breast cancer patients who experienced surgical postponements due to COVID-19 pandemic

Association between Time to Operation and Pathological Stage in DCIS & ER+ Breast Cancer. Courtesy of American College of Surgeons

News | Women's Health | August 07, 2020
August 7, 2020 — A new br...

An oncologist practices social distancing while talking to a cancer patient. Image courtesy of University of Michigan Rogel Cancer Center

News | Coronavirus (COVID-19) | August 07, 2020
August 7, 2020 — When COVID-19 struck, health ca
Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
Intelerad Medical Systems, a leader in enterprise workflow solutions, announced the acquisition of Radius, a private cloud platform provider based in the Nashville, Tenn., metropolitan area.
News | Enterprise Imaging | August 05, 2020
August 5, 2020 — Intelerad Medical Systems, a leader in enterprise workflow solutions, announced the acquisition of
According to the new market research report "Radiation Dose Management Market by Products & Services (Standalone Solutions, Integrated Solutions, Services), Modality (Computed Tomography, Nuclear Medicine), Application (Oncology, Cardiology, Orthopedic), End User (Hospitals) - Global Forecast to 2025", published by MarketsandMarkets, the radiation dose management market is projected to reach USD 422.65 million by 2025 from USD 220.22 million in 2020, at a CAGR of 13.9%.

Courtesy of MarketsandMarkets Research

News | Radiation Dose Management | August 03, 2020
August 3, 2020 — According to the new market research report "...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
Older Americans may be receiving cancer screenings not recommended by the U.S. Preventive Services Task Force, according to Penn State College of Medicine researchers.

Getty Images

News | Radiology Imaging | July 31, 2020
July 31, 2020 — Older Americans may be receiving cancer screenings not recommended by the...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...